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ABSTRACT
Introduction: The opioid epidemic is a modern public health emergency. Common interventions to alleviate the
opioid epidemic aim to discourage excessive prescription of opioids. However, these methods often take place
over large municipal areas (state-level) and may fail to address the diversity that exists within each opioid case
(individual-level). An intervention to combat the opioid epidemic that takes place at the individual-level would
be preferable.
Methods: This research leverages computational tools and methods to characterize the opioid epidemic at the
individual-level using the electronic health record data from a large, academic medical center. To better under-
stand the characteristics of patients with opioid use disorder (OUD) we leveraged a self-controlled analysis to
compare the healthcare encounters before and after an individual’s first overdose event recorded within the
data. We further contrast these patients with matched, non-OUD controls to demonstrate the unique qualities of
the OUD cohort.
Results: Our research confirms that the rate of opioid overdoses in our hospital significantly increased between
2006 and 2015 (P<0.001), at an average rate of 9% per year. We further found that the period just prior to the
first overdose is marked by conditions of pain or malignancy, which may suggest that overdose stems from
pharmaceutical opioids prescribed for these conditions.
Conclusions: Informatics-based methodologies, like those presented here, may play a role in better understand-
ing those individuals who suffer from opioid dependency and overdose, and may lead to future research and
interventions that could successfully prevent morbidity and mortality associated with this epidemic.
Key words: opioid-related disorder, electronic health records, clinical informatics, epidemiology, substance-related disorders
INTRODUCTION
Characterizing the opioid epidemic from a rich and inclusive data
source is a keystone for its abatement. Like the human immunodefi-
ciency virus/Acquired immunodeficiency syndrome crisis, the opioid
epidemic is a modern public health emergency. The human immuno-
deficiency virus/Acquired immunodeficiency syndrome epidemic
reminds us that to effectively combat the opioid epidemic, clinical
interventions should be tailored to treat the affected populations.1,2
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Research and Applications
At present, many strategies toward abatement of the epidemic in-
clude prescription drug monitoring programs (PDMPs) or prescrib-
ing limitations. These methods aim to monitor and limit over-
prescription of opioids and are often enacted at the state-level. How-
ever, such policies can fail to address patterns that occur within the
singular opioid use disorder (OUD) patient. A more informed ap-
proach to combating the epidemic would address opioid cases at the
individual-level. A thorough, longitudinal characterization of OUD
patients may support an individual-level intervention through identi-
fication of patterns of opioid misuse before and after overdose, and
hold the potential for improving quality of care that state-level inter-
ventions may overlook.
Though there are a number of factors theorized to have caused
the epidemic, the unique pharmacology of opioids and increased ad-
vocacy for pain management over the last three decades are likely
contributors.3–5 Opioids are a class of drug that includes prescription
medications such as morphine, and illicit drugs, such as heroin.6
These drugs interact with neuroreceptors to lessen pain-signal percep-
tion.7–9 For this reason opioids remain the most commonly prescribed
drug for the treatment of postoperative, cancer and noncancer pain.10
Opioids can also cause relaxation, sedation, and euphoria9,11 while
repeated use can lead to dependence.12,13 Acute overdose can result in
bradycardia, hypotension, respiratory depression, leading to eventual
respiratory and cardiopulmonary arrest resulting in death.14
The start of the opioid epidemic is widely cited as the mid-
1990s.15–17 There were many contributing factors, including a move-
ment to address untreated pain from the American Pain Society,18
use of opioids for treatment of nonmalignant pain,19 and targeted
marketing of physicians that minimized the addictive potential of
these drugs.20 The number of Americans that have been affected by
opioid misuse has increased. In 2016, 2.1 million Americans were es-
timated to have OUD and nearly 11.8 million Americans reported
opioid misuse in the previous year.21 Between 2001 and 2016, the
percentage of deaths attributable to opioids increased by 292%.22
In response to this crisis, law-makers, researchers, and clinicians
alike have sought to alleviate rising opioid use.23–26 Typically, inter-
ventions for the abatement of the opioid epidemic include policies
enacted at the state- and federal-levels. These include, but are not
limited to PDMPs and prescribing limitations.27 PDMPs are data-
bases that track controlled substance prescriptions within a state
and alert health authorities to behaviors that may contribute to the
epidemic.28 Prescribing limitations are intended to mitigate exces-
sive and unnecessary opioid prescribing through clinical practice
guidelines.29 Though these tactics hold promise, they are applied at
the state- and federal-level and fail to address the precursor charac-
teristics of the individual that may lead a prescription holder to de-
velop OUD and possible overdose. A comprehensive and evidence-
based intervention at the individual-level may be more appropriate.
Such individual-level interventions often begin with a thorough
characterization of the patients in the target cohort.
Target cohorts of OUD patients may be identified through many
data sources. Often, characterizations of the opioid epidemic are
done through the analysis of claims data30,31 or manual review of
clinical documentation.32–35 Administrative claims data, though
longitudinal, may be subject to coding biases and only captures bill-
able encounters for the insured.36,37 Those who abuse substances
comprise a highly marginalized population, where rates of insurance
may be low.38 A recent survey estimates that 20% of adults with
OUD are uninsured.39 The sole use of administrative data may disre-
gard a large portion of the OUD population. These omitted patients
may provide valuable insight into ways to mitigate overdose.
Alternatively, researchers have also engaged in manual review of
medical records, but this may be a time-consuming process and
more susceptible to human error than automated methods.40,41 A
characterization of opioid overdose that is both inclusive and effi-
cient is preferred.
This research leverages the electronic health record (EHR) to
study the opioid epidemic. The EHR is a rich, longitudinal data
source that captures a greater variety of patients and detail than ad-
ministrative data. The EHR may be coupled with informatics meth-
odologies for efficient and accurate research. This presents a
valuable opportunity to not only confirm the frequency of opioid
events, but to characterize the events leading up to and following
the overdose. We present data on all non-heroin opioid overdoses in
the Columbia University Irving Medical Center (CUIMC) EHR. In
addition to tracking the frequency of overdoses, we also contrast the
healthcare utilization in the period prior to and after an individual’s
first overdose. The use of EHR data to investigate opioid overdoses
provides not only a means to uncover overall trends overdoses, but
also supports the identification of healthcare utilization trends that
are common in overdose patients. By characterizing patients accord-
ing to patterns in the EHR, we provide another avenue to support
our understanding of the current epidemic.
MATERIALS AND METHODS
Data and computational tools
This research will leverage EHR data from the CUIMC clinical data
warehouse. The clinical data warehouse contains observational clini-
cal data for 5.37 million individual subjects from 1986 to 2017.
Patients encounters are documented in the EHR at each outpatient,
inpatient, and emergency department (ED) visit. Data modalities in-
clude, but are not limited to, diagnoses, clinical measurements, medi-
cations, and procedures. All CUIMC clinical data warehouse data is
formatted according to the Observational Health Data Science and
Informatics (OHDSI) common data model (CDM).42 Use of CDM-
formatted data will support downstream interoperability of our
methods within the OHDSI community and may promote reproduc-
tion by OHDSI collaborators at other sites. The Columbia University
Medical Center Institutional Review Board approved this study.
Case identification
To investigate overdoses in the CUIMC EHR, we identified all non-
heroin opioid overdoses between January 1, 2006 and December 31,
2015. We mapped validated codes for non-heroin opioid overdo-
ses43 from International Classification of Disease, Ninth Revision,
Clinical Modification (ICD-9-CM)44 to OHDSI concept IDs (Ta-
ble 1). Unique overdose events (encounters) that qualified for this re-
view must have had at least one of these diagnosis codes in an
emergency department or inpatient setting. The results of this query
were used to generate our trend analysis. The encounters where then
used to identify the unique set of overdose patients (cases) which are
used for all later analyses. A single case may have multiple overdose
encounters; we refer to the first of the overdoses as the Index Event.
Other eligibility criteria for identifying cases includes continuous ob-
servation of at least 365 days before and 365 days after first over-
dose. A flow chart of the inclusion criteria when applied to CUIMC
data can be found in the Supplementary File #4.
Trend analysis
The annual increasing rate of opioid overdoses is well docu-
mented.21,32,45–51 To confirm a similar increase, we fit a single effect
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Poisson regression model to model the rate of opioid overdoses. The
number of unique ED and inpatient admissions associated with
overdoses were calculated for each calendar year (2006–2015). We
similarly collected the number of all unique ED and inpatient admis-
sions, regardless of related diagnoses. We then determined the signif-
icance of overdoses per year by modeling the probability of Y events
(opioid overdoses) with E Yð Þ ¼ l during time period t. The log-lin-





¼ b0 þ b1Year
The model was run using the R (R Core Team, Vienna, Austria)
package, glm, to fit generalized linear models, and significance of
parameters was assessed using the Wald Chi-Squared Test.
Demographics
Unlike other data sources that may be limited in scope or incom-
plete, the EHR is a rich record of patient care. To supplement our
confirmation of increasing opioid overdoses, we can additionally
query the EHR to characterize patients over time. We present demo-
graphic data, such as age group, sex, and other variables such as,
healthcare utilization, prescriptions, medical history, and death for a
subset of the opioid overdose case cohort that was identified for the
trend analysis. Because we are interested in a longitudinal character-
ization, this subset of patient’s must have at least 365 days of avail-
able clinical data before and after their index event. Given the
incomplete and inconsistent documentation of race and ethnicity
data in the EHR, we elected to exclude this demographic fea-
ture.52,53
Health care utilization among the opioid-using population is an
important factor to investigate, as metrics of healthcare utilization
may help distinguish misuse from legitimate, but over-prescribed
drugs54–56 and addiction from drug-seeking behaviors.57–59 We ex-
amined healthcare utilization by looking at patterns in the encounter
type. Encounter types include, inpatient stays, outpatient appoint-
ments, and ED visits.
A known factor in the rise of the epidemic is the long-term use and
misuse of prescription drugs.60–64 To better understand patterns of pre-
scription analgesic use, we identified three medication groups of interest
that were defined by the Anatomical Therapeutic Chemical (ATC) Clas-
sification System.65 The drug groups are All Analgesics (ATC N02);
Non-Opioid Analgesics (ATC N02B); and Opioid Analgesics (ATC
N02A). More information on these drug classes can be found in the
Supplementary File #1. Any drug that is a descendant of the ATC class
was included in this analysis. For each of these three medication groups,
we calculated (1) the number of unique patients with a prescription,
and the microaverage (average within a single patient) of (2) the number
of prescriptions, (3) the duration in days of a drug, (4) the quantity of
drug, and (5) the number of refills.
We also present metrics of medical history that address relevant
risk factors for opioid misuse, such as surgical procedures,66–68
substance related disorders,69,70 traumatic injuries,71 and death
(Supplementary File #2).
Rather than presenting a single set of metrics for this case cohort,
we present the same metrics over three periods of interest.1 The Va-
nilla Period, which characterizes the steady-state healthcare utiliza-
tion of patients. We defined this period to be the 6–12 months prior
to each patients’ first overdose.2 The Pre-OD Period, which charac-
terizes the period leading up to the first overdose. We defined this
period to be the 6 months just prior to the overdose, but not includ-
ing the overdose, itself.3 The Post-OD Period, which characterizes
the period directly following the patient’s first overdose. We defined
this period to be the 6 months after the overdose, but not including
the overdose, itself.
To better contextualize the demographic data for the opioid case
cohort, we additionally present all demographic domains for the
three-time periods for the control cohort. To be eligible for the con-
trol cohort, patients must have had at least 365 days of observation,
at least 1 inpatient admission, and could not have any history of sub-
stance abuse (Supplementary File #3). From all eligible controls, a
random sample was selected to match the distribution of age and
sex of the case cohort.
Self-controlled disproportionality analysis
Utilizing the Vanilla Period, Pre-OD Period, and the Post-OD Pe-
riod that were defined above, we implemented a self-controlled dis-
proportionality analysis to identify signals in conditions,
procedures, and pharmacologic ingredients, both leading up to and
directly after the first overdose of patients in the opioid case cohort
(Figure 1). While not causal, this analysis may aid in our under-
standing of patterns that may warn of an impending overdose and
the high-risk complications that follow.
Disproportionality analyses are often used to mine large, obser-
vational databases for signals in observed-to-expected ratios.72–75
The self-controlled disproportionality analysis utilized herein differs
from the traditional method in that each patient serves as their own
control. The benefit of the self-controlled design is that patient-
invariant features will not bias the results.76–79 This is especially im-
portant when investigating opioid overdoses because long-term,
chronic illnesses often require pain management with opioids. To
better understand patterns leading up to the first overdose, we com-
pared the Pre-OD Period with the Vanilla Period, which we call the
Pre-OD Analysis. We then completed the Post-OD Analysis, which
compared the Post-OD Period with the Vanilla Period to under-
stand the window immediately following overdose. For each of these
two experiments, we undertook three disproportionality analyses to
look at exposure signals in (1) conditions, excluding overdose-
related concepts and their descendants, (2) procedures, and (3) med-
ications at the ingredient level.
In both experiments, the data was queried and later analyzed
according to a contingency table preparation. For each period in an
experiment, the observed exposure frequency was recorded as the
Table 1. Mapping of ICD-9CM codes for opioid overdose to OHDSI CDM concept codes
OHDSI ICD-9CM
Concept name ID Concept name ID
Poisoning by opiate AND/OR related narcotic 433083 Poisoning by other opiates and narcotics 965.09
Poisoning by opiate analgesic drug 4084011 Poisoning by opium (alkaloids), unspecified 965.00
Methadone analog poisoning 4156145 Poisoning by methadone 965.02
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count of patients with that exposure in that period. For both experi-
ments, the odds ratio (OR) and 95% confidence interval (CI) for
each exposure was calculated. Exposures with zero counts that
resulted in infinite ORs were excluded.
Heatmap visualization of disproportionality analysis
To better understand patterns in conditions that precede and suc-
ceed an overdose, data from the self-controlled disproportionality
analysis was further analyzed to highlight how comorbidities change
over time. For all conditions, we calculated average per-patient rate
of occurrence, for each month in the 12 months prior to overdose
(Vanilla þ Pre-OD Period) and in the 6 months after overdose
(Post-OD Period). The rate for each condition was then normalized
by the absolute difference between the (1) mean of that conditions
monthly rate in the Post-OD Period, which we call the Macro Mean
Post-OD; and (2) the mean of that conditions monthly rate in the
Vanilla þ Pre-OD Period, which we call the Macro Mean Vanilla þ
Pre-OD.
We calculated the difference between the Macro Mean Post-OD
and the Macro Mean Vanilla þ Pre-OD for each condition. To facil-
itate interpretation of this visualization, we reduce the presented
output and present the 10 conditions with the highest difference in
Macro Means and the 10 conditions with the lowest difference in
Macro Means. The highest difference in Macro Means were posi-
tive, indicating an increased occurrence of this condition in the Post-
OD Period, relative to the Vanilla þ Pre-OD Period. The lowest dif-
ference in Macro Means were negative indicating an increased oc-
currence of this condition in the Vanilla þ Pre-OD Period, relative
to the Post-OD Period.
RESULTS
Case identification
Within the study period, there were 9 498 646 patient encounters to
NewYork-Presbyterian Hospital. Of these patients, 502 (0.005%)
were assigned a diagnosis code associated with a non-heroin opioid
overdose in an inpatient or emergency department setting. We be-
lieve this estimate to be low, as calculation of this prevalence
includes outpatient encounters where acute opioid overdose is
highly unlikely. These encounters correspond to 434 unique patient
cases, of which 379 (87.3%) met the eligibility criteria for inclusion
in our analyses.
Trend analysis
Our trend analysis confirms that, in the years 2006 through
2015, the ratio of opioid overdoses out of all hospital encounters
significantly increased (P<0.001), at an average rate of 9% per
year (95% CI, 5.7–12.5). A plot of the opioid overdose rate over
time is shown in Figure 2.
Demographics
The results of the demographics analysis are shown in Table 2.
Across all periods and medication types, a greater number of opioid
overdose cases had prescriptions for analgesic drugs than the con-
trols. Overdose patients had an increased prevalence of Opioid
Analgesics (ATC N02A), and higher microaverages of number of
prescriptions, days’ duration of medication, and quantity per pre-
scription associated with this drug type. The prevalence of an opioid
prescription increases from 16% in the Vanilla Period to 26% in the
Pre-OD Period for cases. However, the prevalence in the case co-
hort continues to rise to 30% in the Post-OD period.
Self-controlled disproportionality analysis
The results of the self-controlled disproportionality analysis are
shown in Table 3. The top conditions, procedures, and ingredient-
level drugs are ranked by decreasing significance, which is given by
the lower bound of the 95% CI. In both the Pre-OD and Post-OD
Analyses, the highest odds condition is altered mental status, with a
Pre-OD OR of 12.74 (2.99–24.32) and a Post-OD OR of 22.24
(5.33–92.73). Similarly, computerized axial tomography of head is
the highest odds procedure in both analyses, with a Pre-OD OR of
8.85 (2.65–29.57) and a Post-OD OR of 11.56 (3.51–38.08). No
medications were found to be significant in either analysis.
Heatmap visualization of disproportionality analysis
To better understand the significance of our self-controlled dispro-
portionality analysis results, and the progression of opioid overdose,
we additionally visualized the monthly disproportionality analysis
data with a heatmap. The conditions with high absolute mean differ-
ence in normalized rates in the Vanilla & Pre-OD Period (Macro
Average Vanilla & Pre-OD) and the Post-OD Period (Macro Aver-
age Post-OD) are shown in Figure 3.
DISCUSSION
The opioid epidemic continues to be a public health emergency.
While many interventions have focused on rural areas, urban rates
of overdose are on the rise.21 Our research demonstrates that the ep-
idemic is well represented in New York City. Between 2006 and
2015, the rate of opioid overdoses at CUIMC significantly in-
creased, at an average annual rate of 9%. We believe this finding to
be generalizable to other NYC hospitals, as our rate of inpatient and
Figure 1. Schematic of self-controlled disproportionality analysis.
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Figure 2. Rate of opioid overdoses per 100,000 hospital encounters over years 2006-2015.
Table 2. Demographics, healthcare utilization, medication use, and medical history in control and opioid case cohort under varying periods
Random matched
sample of OD
All ODþ Vanilla Period (12
to 6 mo)
Pre-OD Period
(6 to 0 mo)
Post-OD Period
(0 to þ6 mo)
N ¼ 379 379








Average # of visits/year
All visits 11.5 12.1 11.2 11.6
Inpatient 3.6 3.3 3.4 3.5
Outpatient 10.4 14.4 12.0 12.2
Emergency department 4.1 4.4 5.1 5.2
Medications
All analgesics (ATC N02)
# of people with Rx 70 (18%) 107 (28%) 177 (47%) 210 (55%)
Rx/persona 0.93 1.85 3.07 3.84
Days duration/persona 13.46 10.91 9.12 12.88
Quantity/persona 28.65 40.25 41.62 41.73
# refills/persona 1.35 0.62 0.29 0.45
Non-opioid analgesic (ATC N02B)
# of people with Rx 70 (18%) 97 (26%) 166 (44%) 192 (51%)
Rx/persona 0.79 0.98 1.73 2.26
Days duration/persona 14.54 12.15 9.67 15.65
Quantity/persona 28.63 36.12 42.72 40.85
# refills/persona 1.50 0.69 0.40 0.66
Opioid analgesic (ATC N02A)
# of people with Rx 32 (8%) 60 (16%) 99 (26%) 112 (30%)
Rx/persona 0.26 1.11 1.70 1.91
Days duration/persona 6.44 7.26 8.39 8.67
Quantity/persona 31.59 42.17 55.11 40.40
# refills/persona 0.67 0.00 0.12 0.07
History
Surgical procedure 58 (15%) 46 (12%) 73 (19%) 70 (18%)
Substance-related disorder
Alcohol-related 0 (0%) 30 (8%) 49 (13%) 82 (18%)
Drug-related 0 (0%) 79 (21%) 119 (31%) 198 (22%)
Traumatic injury 20 (5%) 30 (8%) 48 (13%) 54 (14%)
Post-OD death rate 0.005
OD: overdose; ODþ: positive for opioid overdose; OD: negative for opioid overdose; Rx: prescription; #: number; ATC: Anatomical Therapeutic Chemical
class.
aMicroaverage.
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Table 3. Results of the self-controlled disproportionality analyses
Pre-OD analysis Post-OD analysis
Concept OR 95% CI Concept OR 95% CI
Top conditions Altered mental status 12.74 2.99–54.32 Altered mental status 22.24 5.33–92.73
Disturbance of consciousness 6.70 1.50–29.88 Acute respiratory failure 13.15 4.01–43.10
Suicidal thoughts 3.86 1.27–11.75 Suicidal deliberate poisoning 16.79 3.99–70.68
Schizoaffective schizophrenia 5.11 1.11–23.47 Pneumonitis due to inhalation
of food or vomitus
8.47 2.53–28.39
Depressive disorder 1.62 1.05–2.51 Suicidal thoughts 6.34 2.18–18.45
Bipolar disorder 2.00 1.03–3.88 Acidosis 8.85 2.03–38.59
Type 2 diabetes mellitus 1.61 1.01–2.58 Disturbance of consciousness 8.85 2.03–38.59
Essential hypertension 1.44 0.99–2.10 Conduction disorder of the heart 5.78 1.97–16.93
Psychotic disorder 2.17 0.97–3.87 Schizoaffective schizophrenia 8.31 1.90–36.39
Top procedures Computerized axial tomography of head 8.85 2.65–29.57 Computerized axial tomography
of head
11.56 3.51–38.08
Insertion of endotracheal tube 6.61 1.94–22.55 Diagnostic ultrasound of heart 6.43 2.47–16.76
Continuous invasive mechanical ventilation
for less than 96 consecutive hours
7.23 1.63–32.04 Diagnostic ultrasound of peripheral
vascular system
5.22 1.77–15.43
Other puncture of vein 2.46 1.57–3.84 Other puncture of vein 2.68 1.72–4.16
Collection of venous blood by
venipuncture
2.37 1.52–3.71 Collection of venous blood by
venipuncture
2.59 1.66–4.03
Diagnostic ultrasound of heart 3.73 1.37–10.15 Injection of anticoagulant 7.23 1.63–32.04
Electrographic monitoring 10.24 1.30–80.43 Therapeutic, prophylactic, or
diagnostic injection
3.65 1.45–9.14










Albuterol 3.02 0.31–29.13 Methadone 1.82 0.60–5.48
Methadone 0.80 0.21–2.99 Albuterol 5.05 0.59–43.46
Ipratropium 2.01 0.18–22.21 Glucose 0.66 0.11–4.00
Tiotropium 1.00 0.06–16.05 Tiotropium 1.00 0.06–16.05
Clonidine 1.00 0.06–16.05 Prednisone 1.00 0.06–16.05
Figure 3. Heatmap of the 10 highest condition rates per month in the Vanilla & Pre-OD period and the Post-OD period.
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emergency department overdoses coincides with the rates reported
for New York City.80
The results of our demographics analysis demonstrate that our
case cohort is similar in many respects to published research on this
disease process.80 Our cohort was predominantly adult patients
greater than 25 years old (84%) and male (62%).
A larger proportion of cases had prescriptions for analgesic drugs
in all study periods compared to the control. When examining Opi-
oid Analgesic (ATC N02A), 8% of the controls held prescriptions
for this medication class, while those cases had notably increased
opioid prescriptions in all study periods (16%–30%). This implies
that those with opioid prescriptions are at increased risk for over-
dose.81 Surprisingly, the proportion of patients with Opioid Analge-
sic prescriptions increased with each study period. This may imply
that the prescribing providers were unaware of prior overdoses and
existing opioid prescriptions, possible because New York’s PDMP
requirement did not go into effect until 2013. Additionally, while
both the cases and controls had durations of prescriptions outside
the CDC recommended period of 3 days for acute pain,82 we see
longer durations with the opioid cases, with an average of 8.39 days
in the Pre-OD Period and 8.67 days in the Post-OD period. This
suggests that longer duration of opioid prescriptions can be associ-
ated with overdose events.
The self-controlled disproportionality analyses, Pre-OD Analysis
and Post-OD Analysis, highlight trends in procedures, medications,
and conditions that characterize the progression of our opioid case
population.
Procedures
The high-odds procedures in the Pre-OD Analysis, such as comput-
erized axial tomography of head, insertion of endotracheal tube, di-
agnostic ultrasound of the heart, electrographic monitoring, and
continuous invasive [mechanical ventilation], may indicate that a
traumatic injury, intensive care medical treatment, or scheduled sur-
gical procedure took place just prior to the first opioid overdose.
Traumatic injuries and surgical procedures have been associated
with continued opioid use,83 though we cannot demonstrate causal-
ity here. Similar high-odds procedures are seen in the Post-OD Anal-
ysis, which may indicate that further traumatic injuries, or
evaluations for toxidromes and altered mental states are associated
after overdose, as well.
Diagnostic imaging, such as computerized axial tomography of
head, may be part of the workup for mental status changes in the ab-
sence of other identifiable causes.84 Subsequent traumatic injuries,
psychiatric evaluations, or overdoses may be the attributable to the
increase in odds of many diagnostic images from the Pre-OD to the
Post-OD Period. In the Post-OD Analysis, we also see diagnostic ul-
trasound of peripheral vascular system, which was not present in the
other experiment. There is a well-documented transition from pre-
scription opioid abuse to intravenous heroin,85 which increases risk
of venous sclerosis and the need for this procedure.
In general, the associations we have identified between proce-
dures and opioid overdose cannot impart causality. However, proce-
dure codes represent a unique perspective on clinical care that is
worthy of analysis. Unlike medications or diagnosis codes which
may follow patients through various episodes of care, procedures
are predominantly associated with a distinct encounter—such as a
chest x-ray during an emergency department visit—and usually re-
quired for billing. Therefore, we can have a high level of confidence
in trends we have identified in our results, despite uncertainty in
their cause. Further research on the relationships between opioid
overdoses and procedures could aid in our understanding of this
complex and at-risk patient population.
Ingredient-level drugs
Our results demonstrate that no medications at the ingredient-level
were found to be significant in either our Pre-OD or Post-OD ex-
periment, though we find interest in the relative rank of methadone
Post-OD. Methadone is a synthetic opioid typically used for
medication-assisted therapy (MAT) of OUD.86 In the Pre-OD Anal-
ysis, methadone is the second most common ingredient, with a non-
significant OR estimate of 0.80. In the Post-OD Analysis,
methadone is the highest rank ingredient, with an estimated OR of
1.82. The change in both the rank and the estimate, though nonsig-
nificant, indicates possible actions to treat OUD with MAT. The in-
crease in MAT, coupled with the increase in opioid prescriptions
seen in the Demographics Analysis, may indicate the presence of
two cohorts: one where patients continue opioid use after overdose,
and one where patients seek treatment with MAT.
Conditions
Our results from the self-controlled disproportionality analysis of
conditions highlight the close relationship between drug abuse and
mental health.87,88 High OR conditions, such as altered mental sta-
tus, suicidal thoughts, schizoaffective schizophrenia, bipolar disor-
der, suicidal deliberate poisoning, and psychotic disorder are
common in both the Pre-OD and Post-OD Analyses. However, con-
ditions that typically result from overdose are unique to the Post-
OD period; these include acute respiratory failure,89,90 pneumonitis
due to inhalation of food or vomitus,91 acidosis,92 and conduction
disorder of the heart.93
Heatmap visualization of disproportionality analysis
Conditions that traditionally merit opioid prescription have dispro-
portionately higher rates in the Vanilla þ Pre-OD Period than the
Post-OD Period. These include conditions of (1) pain, such as shoul-
der pain and neck pain, (2) cancer-related conditions, such as pri-
mary malignant neoplasm of the brain and spinal cord; respiratory
track; rectum; and head, neck, and face, (3) and injury, shown here
as intracranial injury. We also see mental health conditions of bipo-
lar (affective) and adjustment (disorder). These results are con-
trasted by the Post-OD Period, where we see many condition
associated with (1) prolonged opioid misuse, such as acute respira-
tory failure, congestive heart failure, viral hepatitis C,94 and contin-
uous opioid dependence, and (2) continuing mental health issues,
including suicidal deliberate poisoning; depressive disorder; and al-
tered mental status. This visualization of the self-controlled dispro-
portionality analysis data highlights that the Vanilla þ Pre-OD
Period is marked by high pain conditions, which may suggest that
opioid overdose stems from pharmaceutical opioids prescribed for
the treatment of these conditions. The Post-OD Period is distin-
guished by complications of prolonged opioid use. However, in both
Periods, mental health appears to be a strong associational condition
to overdose.
LIMITATIONS
This research has some limitations. As with all analyses of EHR
data, the results of this research may be both biased by the inaccu-
rate or incomplete recording of clinical encounters, or may be reflec-
tive of institutional practices that impede generalizability.95,96
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The results presented in this article represent only a single site, and
as such the external validity of these findings are limited. In our self-
controlled disproportionality analysis, because we were interested in
characterizing the Post-OD Period, we restricted our inquiry to non-
fatal opioid cases. As such, patients with fatal overdoses are not
characterized. Additionally, the span of time assigned to the Vanilla,
Pre-OD, and Post-OD Periods was somewhat arbitrary. More in-
formative windows may exist. Furthermore, this is a retrospective
analysis, and as such, strong assumptions and specialized methodol-
ogy would be required to investigate causal relationships.
CONCLUSIONS
This research characterizes OUD patients, their care trajectory near
an overdose event, and may illuminate aspects of the opioid epi-
demic. Using the EHR data at CUIMC, we are able to confirm a rise
in non-heroin opioid overdoses. Unlike characterizations of the epi-
demic, our use of the EHR and informatics methodologies provides
invaluable insights into the overdose patients and characteristics of
their healthcare utilization surrounding the first, nonlethal overdose.
The results of this analysis suggest that on the individual-level, the
continuum of the epidemic may begin with condition occurrences
associated with pain that may be tied to legitimate opioid prescrip-
tions. This finding suggests that clinicians should consider the possi-
bility that OUD may develop in medically necessary scenarios, and
lead to an overdose in the short term. The patterns in condition di-
agnosis and drug prescription may also be used to inform policies
surrounding the opioid-epidemic.
This research further suggests that the medical and research com-
munities should explore informatics methods for novel ways to ex-
plore this epidemic. Ubiquitous and computable data sources, like
the EHR, may allow researchers to study a wider breadth of patients
and efficiently analyze their characteristics. When coupled with
established informatics-based methodologies, like those presented
here, the EHR may be able to play a role in better understanding
those individuals who suffer from OUD and overdose. A better un-
derstanding of the events and medically relevant characteristics asso-
ciated with patients with OUD may lead to future research and
interventions that could successfully prevent morbidity and mortal-
ity associated with the epidemic.
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